The phase II cohort-based study revealed that out of 126 individuals diagnosed with advanced KRAS-G12C-mutant NSCLC, sotorasib treatment resulted in confirmed ORR and disease control rates (DCR) of 37.1% and 80.6%, respectively. Here, KRAS is linked to non-small cell lung carcinoma.